Ivc Wealth Advisors LLC Cassava Sciences Inc Transaction History

Ivc Wealth Advisors LLC

$181 Million
Q3 2024

A detailed history of Ivc Wealth Advisors LLC transactions in Cassava Sciences Inc stock. As of the latest transaction made, Ivc Wealth Advisors LLC holds 12,673 shares of SAVA stock, worth $332,159. This represents 0.2% of its overall portfolio holdings.

Number of Shares

12,673

Previous 13,373 5.23%

Holding current value

$332,159

Previous $165,000 125.45%

% of portfolio

0.2%

Previous 0.09%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 24, 2024	SELL	$9.57 - $35.08 $6,699 - $24,556	-700 Reduced 5.23%	12,673 $372,000
Q4 2023 Jan 10, 2024	SELL	$12.64 - $30.11 $36,972 - $88,071	-2,925 Reduced 17.95%	13,373 $301,000
Q2 2023 Jul 13, 2023	BUY	$21.59 - $27.88 $56,134 - $72,488	2,600 Added 18.98%	16,298 $399,000
Q1 2023 Apr 13, 2023	SELL	$23.46 - $36.44 $37,536 - $58,304	-1,600 Reduced 10.46%	13,698 $330,000
Q4 2022 Jan 17, 2023	BUY	$27.82 - $44.16 $13,437 - $21,329	483 Added 3.26%	15,298 $0
Q3 2022 Oct 12, 2022	BUY	$16.33 - $51.06 $6,531 - $20,424	400 Added 2.77%	14,815 $620,000
Q2 2022 Jul 11, 2022	BUY	$17.22 - $38.47 $2,152 - $4,808	125 Added 0.87%	14,415 $405,000
Q1 2022 Apr 27, 2022	BUY	$32.6 - $53.05 $55,909 - $90,980	1,715 Added 13.64%	14,290 $531,000
Q4 2021 Jan 13, 2022	BUY	$36.77 - $90.91 $99,279 - $245,457	2,700 Added 27.34%	12,575 $550,000
Q3 2021 Oct 08, 2021	SELL	$41.79 - $135.3 $835 - $2,706	-20 Reduced 0.2%	9,875 $613,000
Q2 2021 Jul 13, 2021	BUY	$32.15 - $89.72 $97,253 - $271,403	3,025 Added 44.03%	9,895 $845,000
Q1 2021 Apr 20, 2021	BUY	$7.09 - $87.95 $48,708 - $604,216	6,870 New	6,870 $309,000

Others Institutions Holding SAVA

# of Institutions

187

Shares Held

13.5M

Call Options Held

1.42M

Put Options Held

2.05M

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $1.05B
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ivc Wealth Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ivc Wealth Advisors LLC with notifications on news.

Account

Ivc Wealth Advisors LLC Cassava Sciences Inc Transaction History